02151nas a2200289 4500000000100000008004100001260002100042653002200063653001400085653003900099653003100138100001400169700002100183700001900204700001800223700001800241700001500259700001600274700001600290700001500306245008800321856006800409300001000477490000700487520135300494022001401847 2026 d c08/2026bMDPI AG10aSurvival Analysis10aTreatment10a Leishmania (Viannia) braziliensis10adisseminated leishmaniasis1 aLeal JFDC1 aBezerra Silva CC1 aNascimento MBS1 aGonçalves RT1 aFernandes LHG1 aCampos ASC1 aAraújo FMD1 aSampaio RNR1 aBarroso DH00aSurvival Analysis in Cutaneous Leishmaniasis Patients: A Retrospective Cohort Study uhttps://www.mdpi.com/2227-9059/14/8/1762/pdf?version=1785918265 a1 - 90 v143 a

Background/Objectives:

American Tegumentary leishmaniasis typically presents as a single ulcerative lesion, but atypical clinical forms exist with diverse physiopathology and treatment responses. Disseminated cutaneous leishmaniasis is a less common presentation that is often challenging to treat and for which evidence-based clinical decisions are scant. A better understanding of treatment response may support the development of alternative therapeutic strategies. This study reports a retrospective cohort analysis using a time-to-event outcome to compare disseminated leishmaniasis with localized cutaneous leishmaniasis using a multivariate model.

Methods:

A total of 366 patients were screened for inclusion between 2014 and 2024, of whom 123 met the inclusion criteria.

Results:

After adjustment for age and sex, patients with disseminated cutaneous leishmaniasis had a significantly longer time to healing than those with localized cutaneous leishmaniasis (HR = 0.29; p = 0.021).

Conclusions:

Disseminated cutaneous leishmaniasis seems to be an important predictor of poorer clinical outcomes with prolonged healing time. New therapeutic strategies are urgently needed to address this issue.

 a2227-9059